Becton, Dickinson and Company $BDX Shares Sold by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 117,941 shares of the medical instruments supplier’s stock after selling 24,239 shares during the period. Caisse de depot et placement du Quebec’s holdings in Becton, Dickinson and Company were worth $17,848,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Man Group plc grew its stake in shares of Becton, Dickinson and Company by 30.9% during the second quarter. Man Group plc now owns 18,549 shares of the medical instruments supplier’s stock worth $2,807,000 after purchasing an additional 4,384 shares in the last quarter. First Bancorp Inc ME purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $104,000. Roberts Glore & Co. Inc. IL increased its holdings in shares of Becton, Dickinson and Company by 1.0% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 8,414 shares of the medical instruments supplier’s stock valued at $1,273,000 after acquiring an additional 85 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth about $75,944,000. Finally, Ancora Advisors LLC lifted its stake in Becton, Dickinson and Company by 1.8% during the second quarter. Ancora Advisors LLC now owns 5,967 shares of the medical instruments supplier’s stock worth $903,000 after purchasing an additional 106 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $189.71 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07. The stock’s 50-day moving average price is $166.14 and its 200 day moving average price is $160.53. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $52.27 billion, a PE ratio of 57.14, a price-to-earnings-growth ratio of 13.26 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the business posted $3.68 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,869 shares of company stock worth $1,994,719 over the last quarter. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on BDX. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group reduced their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Barclays lifted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.